AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 21777507 — intervention group
Group type: EXPERIMENTAL
Intervention: Paliperidone palmitate (PP): 50 mg eq. on days 1 and 8, flexible dosing 25-100 mg eq. once-monthly
Number of subjects: 749
Study 21777507 — intervention group
Group type: COMPARATOR
Intervention: Risperidone long-acting injectable (RIS-LAI): bi-weekly injections of 25 mg on days 8 and 22, flexible dosing (25-50 mg) starting from day 36
Number of subjects: 749
Study 21777507 — intervention group
Group type: EXPERIMENTAL
Intervention: Both treatments (PP and RIS-LAI)
Number of subjects: 749
Study 19476477 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled TI (25 U)
Number of subjects: 11
Study 19476477 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled TI (50 U)
Number of subjects: 11
Study 19476477 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled TI (100 U)
Number of subjects: 11
Study 19476477 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous RHI (10 IU)
Number of subjects: 11
Study 17541337 — intervention group
Group type: EXPERIMENTAL
Intervention: Saliva samples
Number of subjects: 274
Study 17541337 — intervention group
Group type: COMPARATOR
Intervention: Blood samples
Number of subjects: 274
Study 17541337 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population
Number of subjects: 274
Study 15051600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-oleate meal (50 g fat)
Number of subjects: 51
Study 15051600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-palmitate meal (50 g fat)
Number of subjects: 51
Study 15051600 — intervention group
Group type: COMPARATOR
Intervention: Low-fat meal (15 g fat)
Number of subjects: 51
Study 15051600 — intervention group
Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 51
Study 12113542 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing (chewed three times a day from the first postoperative AM until oral intake)
Number of subjects: 19
Study 12113542 — intervention group
Group type: EXPERIMENTAL
Intervention: Gum chewing
Number of subjects: 19
Study 12113542 — intervention group
Group type: COMPARATOR
Intervention: Control (no gum chewing)
Number of subjects: 19
Study 12113542 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 19
Study 9728846 — intervention group
Group type: EXPERIMENTAL
Intervention: IV amino acid mixture, 240 kJ/h before and during anesthesia
Number of subjects: 24
Study 9728846 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetated Ringer's solution during isoflurane anesthesia
Number of subjects: 24
Study 9728846 — intervention group
Group type: COMPARATOR
Intervention: Awake controls (no anesthesia or surgery)
Number of subjects: 24
Study 7651785 — intervention group
Group type: EXPERIMENTAL
Intervention: Exclusive breast‐feeding with addition of hygienically prepared, nutritionally adequate complementary foods at 4 months
Number of subjects: 141
Study 7651785 — intervention group
Group type: COMPARATOR
Intervention: Exclusive breast‐feeding to 6 months
Number of subjects: 141
Study 7651785 — intervention group
Group type: EXPERIMENTAL
Intervention: Honduran infants (n = 141)
Number of subjects: 141
Study 2491990 — intervention group
Group type: EXPERIMENTAL
Intervention: Short-term administration of Buserelin (day 1)
Number of subjects: 18
Study 2491990 — intervention group
Group type: COMPARATOR
Intervention: Long-term protocol (day 21)
Number of subjects: 18
Study 2491990 — intervention group
Group type: COMPARATOR
Intervention: Control group (13 patients)
Number of subjects: 18
Study 1120556 — intervention group
Group type: EXPERIMENTAL
Intervention: Perexiline maleate at 400 mg/die
Number of subjects: 16
Study 1120556 — intervention group
Group type: COMPARATOR
Intervention: Prenilamine at 120 mg/die
Number of subjects: 16
Study 1120556 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 30102427 — intervention group
Group type: COMPARATOR
Intervention: BUP/SAM 2 mg/2 mg
Number of subjects: 0
Study 30102427 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP/SAM at 4-fold (8 mg/8 mg) and 8-fold (16 mg/16 mg) the therapeutic dose
Number of subjects: 0
Study 30102427 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine alone (8 mg and 16 mg)
Number of subjects: 0
Study 30102427 — intervention group
Group type: EXPERIMENTAL
Intervention: BUP/SAM
Number of subjects: 0
Study 29045326 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (40 min of submaximal high-intensity interval cycling)
Number of subjects: 10
Study 29045326 — intervention group
Group type: EXPERIMENTAL
Intervention: Strawberry (25 g freeze-dried strawberries)
Number of subjects: 10
Study 29045326 — intervention group
Group type: COMPARATOR
Intervention: Placebo (strawberry flavoring)
Number of subjects: 10
Study 26348160 — intervention group
Group type: EXPERIMENTAL
Intervention: Early value system activated by negative outcomes
Number of subjects: 0
Study 26348160 — intervention group
Group type: EXPERIMENTAL
Intervention: Late value system responding to outcomes
Number of subjects: 0
Study 26348160 — intervention group
Group type: EXPERIMENTAL
Intervention: Thalamostriatal pathway interaction
Number of subjects: 0
Study 23385795 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical moxifloxacin
Number of subjects: 500
Study 23385795 — intervention group
Group type: EXPERIMENTAL
Intervention: Moxifloxacin susceptibility
Number of subjects: 500
Study 21206932 — intervention group
Group type: EXPERIMENTAL
Intervention: NitrAdine tablets
Number of subjects: 70
Study 21206932 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 18083355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar diet (70% energy from carbohydrate)
Number of subjects: 12
Study 18083355 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet (50% energy from fat)
Number of subjects: 12
Study 18083355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-starch diet (70% energy from carbohydrate)
Number of subjects: 12
Study 18083355 — intervention group
Group type: COMPARATOR
Intervention: High-fat diet
Number of subjects: 12
Study 18083355 — intervention group
Group type: EXPERIMENTAL
Intervention: High-sugar diet
Number of subjects: 12
Study 17437826 — intervention group
Group type: EXPERIMENTAL
Intervention: Burch colposuspension
Number of subjects: 655
Study 17437826 — intervention group
Group type: COMPARATOR
Intervention: Pubovaginal sling
Number of subjects: 655
Study 17437826 — intervention group
Group type: EXPERIMENTAL
Intervention: Supine empty bladder stress test
Number of subjects: 655
Study 17437826 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva leak point pressure measurements
Number of subjects: 655
Study 17437826 — intervention group
Group type: EXPERIMENTAL
Intervention: Medical, Epidemiological and Social Aspects of Aging
Number of subjects: 655
Study 17437826 — intervention group
Group type: EXPERIMENTAL
Intervention: Incontinence Impact Questionnaire
Number of subjects: 655
Study 17437826 — intervention group
Group type: EXPERIMENTAL
Intervention: Urogenital Distress Inventory
Number of subjects: 655
Study 17437826 — intervention group
Group type: EXPERIMENTAL
Intervention: Valsalva leak point pressure
Number of subjects: 655
Study 15548480 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 g mucuna preparation
Number of subjects: 8
Study 15548480 — intervention group
Group type: COMPARATOR
Intervention: LD/CD
Number of subjects: 8
Study 11305824 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25% with epinephrine 1:200,000 infiltrations (10 ml into the portals, 10 ml at the medial tibial incision site, 10 ml at the lateral femoral incision site, and 10 ml intra-articularly presurgically; 5 ml at the medial tibial incision and 10 ml at the lateral femoral incision postsurgically)
Number of subjects: 23
Study 11305824 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9% infiltrations (same administration as treatment group)
Number of subjects: 23
Study 9158385 — intervention group
Group type: EXPERIMENTAL
Intervention: Trimetazidine treatment started twenty-four hours after percutaneous transluminal coronary angioplasty (PTCA) in 26 patients (Group I)
Number of subjects: 51
Study 9158385 — intervention group
Group type: COMPARATOR
Intervention: Control group without trimetazidine treatment (25 patients, Group II)
Number of subjects: 51
Study 8502506 — intervention group
Group type: EXPERIMENTAL
Intervention: Antenatal corticosteroids (ANCS)
Number of subjects: 239
Study 8502506 — intervention group
Group type: COMPARATOR
Intervention: No antenatal corticosteroids (Control)
Number of subjects: 239
Study 2437347 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextran sulfate (mild anticoagulant) for 7 to 56 months (average, 25.4 months)
Number of subjects: 246
Study 2437347 — intervention group
Group type: COMPARATOR
Intervention: Natural history (conservative management with serial measurements of GFR)
Number of subjects: 246
Study 31176888 — intervention group
Group type: EXPERIMENTAL
Intervention: Prolonged exposure therapy (PE)
Number of subjects: 200
Study 31176888 — intervention group
Group type: COMPARATOR
Intervention: Present-centered therapy (PCT)
Number of subjects: 200
Study 28634985 — intervention group
Group type: EXPERIMENTAL
Intervention: Korean version of the Affective Go/No-Go test
Number of subjects: 15
Study 28634985 — intervention group
Group type: COMPARATOR
Intervention: English version of the Affective Go/No-Go test
Number of subjects: 15
Study 27421623 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose fluocinolone acetonide implant (FAi)
Number of subjects: 11
Study 27421623 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose fluocinolone acetonide implant (FAi)
Number of subjects: 11
Study 27421623 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluocinolone acetonide implant (FAi)
Number of subjects: 11
Study 25042693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil (20mg 3× daily)
Number of subjects: 22
Study 25042693 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 22
Study 25042693 — intervention group
Group type: EXPERIMENTAL
Intervention: Sildenafil
Number of subjects: 22
Study 25042693 — intervention group
Group type: COMPARATOR
Intervention: Sildenafil and Placebo
Number of subjects: 22
Study 23077913 — intervention group
Group type: EXPERIMENTAL
Intervention: Indirect veneers (Group A)
Number of subjects: 0
Study 23077913 — intervention group
Group type: COMPARATOR
Intervention: Direct veneers (Group B)
Number of subjects: 0
Study 20357377 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonremovable fiberglass off‐bearing cast (TCC group)
Number of subjects: 45
Study 20357377 — intervention group
Group type: EXPERIMENTAL
Intervention: Removable cast walker (Stabil‐D group)
Number of subjects: 45
Study 18277899 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX)
Number of subjects: 44
Study 18277899 — intervention group
Group type: EXPERIMENTAL
Intervention: Methotrexate (MTX) for steroid-dependent CD patients
Number of subjects: 44
Study 16117698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixed brimonidine/timolol BID (n = 385)
Number of subjects: 1159
Study 16117698 — intervention group
Group type: COMPARATOR
Intervention: Brimonidine 0.2% TID (n = 382)
Number of subjects: 1159
Study 16117698 — intervention group
Group type: COMPARATOR
Intervention: Timolol 0.5% BID (n = 392)
Number of subjects: 1159
Study 11967597 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of subglottic area (SDSA) using a continuous infusion of a suspension containing polymyxin, tombramycin, and amphotericin B (n=30)
Number of subjects: 79
Study 11967597 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n=31)
Number of subjects: 79
Study 11967597 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective decontamination of subglottic area (SDSA)
Number of subjects: 79
Study 11967597 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 79
Study 9989716 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose hydrocortisone (5 mg or 10 mg daily) for 1 month
Number of subjects: 32
Study 9989716 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 1 month
Number of subjects: 32
Study 8528370 — intervention group
Group type: EXPERIMENTAL
Intervention: Tacrine treatment for 14 months
Number of subjects: 20
Study 8528370 — intervention group
Group type: COMPARATOR
Intervention: Untreated group (control)
Number of subjects: 20
Study 2181748 — intervention group
Group type: EXPERIMENTAL
Intervention: Local oestrogen in the vagina
Number of subjects: 23
Study 2181748 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 23
Study 7351606 — intervention group
Group type: EXPERIMENTAL
Intervention: Bethanechol
Number of subjects: 45
Study 7351606 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 28304146 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide 1.8 mg
Number of subjects: 26
Study 28304146 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 26030324 — intervention group
Group type: EXPERIMENTAL
Intervention: Cycle-ergometer exercise at 60% of the patients' maximal oxygen uptake (∼35 W)
Number of subjects: 11
Study 26030324 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls (7 subjects)
Number of subjects: 11
Study 26030324 — intervention group
Group type: EXPERIMENTAL
Intervention: McArdle patients during exercise
Number of subjects: 11
Study 24130358 — intervention group
Group type: EXPERIMENTAL
Intervention: Salsalate 3.5 g/day
Number of subjects: 88
Study 24130358 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 88
Study 21356021 — intervention group
Group type: EXPERIMENTAL
Intervention: Stannous chloride/sodium fluoride dentifrice (SnCl(2)/NaF, blend-a-med(®) Pro Expert)
Number of subjects: 27
Study 21356021 — intervention group
Group type: COMPARATOR
Intervention: Sodium fluoride dentifrice (NaF, Sensodyne(®) ProNamel(™))
Number of subjects: 27
Study 19709676 — intervention group
Group type: EXPERIMENTAL
Intervention: Tysabri (Natalizumab)
Number of subjects: 0
Study 19709676 — intervention group
Group type: EXPERIMENTAL
Intervention: Poisson-type regressions for count data
Number of subjects: 0
Study 19709676 — intervention group
Group type: EXPERIMENTAL
Intervention: Cox proportional hazards models for time to relapse
Number of subjects: 0
Study 16566033 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alfa‐2a with ribavirin
Number of subjects: 29
Study 16566033 — intervention group
Group type: COMPARATOR
Intervention: Peginterferon alfa‐2a without ribavirin (control)
Number of subjects: 29
Study 15982963 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-Program service contact Days (OD) during Treatment (DT)
Number of subjects: 88
Study 15982963 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-Program service contact Days (OD) at 3 months (3-M)
Number of subjects: 88
Study 15982963 — intervention group
Group type: EXPERIMENTAL
Intervention: Out-of-Program services between 3 and 9 months post-treatment
Number of subjects: 88
Study 11728816 — intervention group
Group type: EXPERIMENTAL
Intervention: Apocynin (3 ml of 0.5 mg/ml) inhaled 2 times before and 6 times after O(3) exposure
Number of subjects: 7
Study 11728816 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 7
Study 9041330 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected subjects with <200 CD4 cells/microL
Number of subjects: 142
Study 9041330 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected subjects with >= 200 CD4 cells/microL
Number of subjects: 142
Study 9041330 — intervention group
Group type: COMPARATOR
Intervention: Non-HIV-infected controls
Number of subjects: 142
Study 9041330 — intervention group
Group type: EXPERIMENTAL
Intervention: HIV-infected subjects
Number of subjects: 142
Study 7877064 — intervention group
Group type: EXPERIMENTAL
Intervention: Screening group (N = 4691)
Number of subjects: 9300
Study 7877064 — intervention group
Group type: COMPARATOR
Intervention: Control group (N = 4619)
Number of subjects: 9300
Study 3350281 — intervention group
Group type: EXPERIMENTAL
Intervention: Omeprazole (20 mg daily)
Number of subjects: 169
Study 3350281 — intervention group
Group type: COMPARATOR
Intervention: Cimetidine (600 mg twice daily)
Number of subjects: 169
Study 31559587 — intervention group
Group type: EXPERIMENTAL
Intervention: Right pericardial window (RPW)
Number of subjects: 120
Study 30110007 — intervention group
Group type: EXPERIMENTAL
Intervention: Ulinastatin (2×10^4 U/kg)
Number of subjects: 40
Study 30110007 — intervention group
Group type: COMPARATOR
Intervention: Normal saline (50 mL)
Number of subjects: 40
Study 27717299 — intervention group
Group type: EXPERIMENTAL
Intervention: Niraparib (300 mg once daily)
Number of subjects: 553
Study 24099637 — intervention group
Group type: EXPERIMENTAL
Intervention: Levodopa (L-Dopa; 100 mg)
Number of subjects: 34
Study 24099637 — intervention group
Group type: EXPERIMENTAL
Intervention: Haloperidol (2 mg)
Number of subjects: 34
Study 24099637 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 22562746 — intervention group
Group type: EXPERIMENTAL
Intervention: Linear periodization (LP)
Number of subjects: 28
Study 22562746 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily undulating periodization (DUP)
Number of subjects: 28
Study 22562746 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 28
Study 19373103 — intervention group
Group type: EXPERIMENTAL
Intervention: Very deep sclerectomy with collagen implant (VDSCI)
Number of subjects: 48
Study 19373103 — intervention group
Group type: COMPARATOR
Intervention: Deep sclerectomy with collagen implant (DSCI)
Number of subjects: 48
Study 18835931 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic peptide (ANP) infusion (25 ng . kg(‐1) . min(‐1))
Number of subjects: 12
Study 15043569 — intervention group
Group type: EXPERIMENTAL
Intervention: 100 microg lenograstim daily
Number of subjects: 33
Study 15043569 — intervention group
Group type: EXPERIMENTAL
Intervention: 250 microg lenograstim daily
Number of subjects: 33
Study 11355564 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose albendazole (400 mg for 3 consecutive days) plus praziquantel (40 mg/kg) plus iron supplementation (ferrous fumarate 200 mg weekly for 10 weeks)
Number of subjects: 428
Study 11355564 — intervention group
Group type: EXPERIMENTAL
Intervention: Single-dose albendazole (400 mg) plus praziquantel (40 mg/kg)
Number of subjects: 428
Study 11355564 — intervention group
Group type: EXPERIMENTAL
Intervention: Triple-dose albendazole (400 mg for 3 consecutive days) plus praziquantel (40 mg/kg)
Number of subjects: 428
Study 11355564 — intervention group
Group type: COMPARATOR
Intervention: Control group (no anthelmintic treatment)
Number of subjects: 428
Study 11355564 — intervention group
Group type: EXPERIMENTAL
Intervention: Regular 6-monthly anthelmintic treatment
Number of subjects: 428
Study 9626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanidazole (dose levels between 3 and 5.5 g/m2/day, total doses of 12, 16, 20, and 22 g/m2)
Number of subjects: 55
Study 9626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanidazole (16 g/m2 dose level)
Number of subjects: 55
Study 9626461 — intervention group
Group type: EXPERIMENTAL
Intervention: Etanidazole
Number of subjects: 55
Study 9626461 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose ICE (ifosfamide, carboplatin, etoposide)
Number of subjects: 55
Study 8142225 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-protein formula (P:E ratio 5.6%)
Number of subjects: 24
Study 8142225 — intervention group
Group type: COMPARATOR
Intervention: Control protein formula (P:E ratio 10.4%)
Number of subjects: 24
Study 3144513 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (one-dose pretreatment)
Number of subjects: 13
Study 3144513 — intervention group
Group type: EXPERIMENTAL
Intervention: Budesonide (4 weeks pretreatment)
Number of subjects: 13
Study 3144513 — intervention group
Group type: EXPERIMENTAL
Intervention: Disodium cromoglycate (one-dose pretreatment)
Number of subjects: 13
Study 3144513 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbutaline (one-dose pretreatment)
Number of subjects: 13
Study 3144513 — intervention group
Group type: COMPARATOR
Intervention: Placebo challenge
Number of subjects: 13
Study 3144513 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine challenge
Number of subjects: 13
Study 29220704 — intervention group
Group type: EXPERIMENTAL
Intervention: Heavier peers
Number of subjects: 0
Study 29220704 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 27197868 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranibizumab injections
Number of subjects: 2227
Study 25545856 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning assessment of cold pain threshold (in seconds)
Number of subjects: 48
Study 25545856 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning assessment of cold pain threshold (in °C)
Number of subjects: 48
Study 25545856 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning assessment of cold pain intensity
Number of subjects: 48
Study 25545856 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning assessment of cold pain tolerance
Number of subjects: 48
Study 25545856 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning assessment of heat pain threshold
Number of subjects: 48
Study 25545856 — intervention group
Group type: EXPERIMENTAL
Intervention: Morning assessment of heat pain intensity
Number of subjects: 48
Study 25545856 — intervention group
Group type: COMPARATOR
Intervention: Mechanical pain parameters
Number of subjects: 48
Study 25545856 — intervention group
Group type: COMPARATOR
Intervention: Dynamic pain paradigms (temporal summation and conditioned pain modulation)
Number of subjects: 48
Study 23807156 — intervention group
Group type: EXPERIMENTAL
Intervention: Elvitegravir once daily
Number of subjects: 702
Study 23807156 — intervention group
Group type: COMPARATOR
Intervention: Raltegravir twice daily
Number of subjects: 702
Study 20653670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily)
Number of subjects: 96
Study 20653670 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg once daily) + Placebo
Number of subjects: 96
Study 20653670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily) in patients with pre-treatment scores >18
Number of subjects: 96
Study 20653670 — intervention group
Group type: EXPERIMENTAL
Intervention: Lansoprazole (30 mg once daily) + Mosapride (5 mg three times daily) in second phase
Number of subjects: 96
Study 20653670 — intervention group
Group type: COMPARATOR
Intervention: Lansoprazole (30 mg once daily) + Placebo in second phase
Number of subjects: 96